Chitinase‑like proteins (CLPs), long recognized as biomarkers of inflammation and airway damage in asthma, play a far more direct and powerful role in shaping the disease than previously understood. Findings from the study, “Allergen-Induced Airway Matrix Remodeling in Mice Can be Prevented or Reversed by Targeting Chitinase-Like Proteins,” shed new light on the biological mechanisms behind chronic asthma and open the door to potential therapeutic strategies targeting structural lung changes rather than inflammation alone. The study was published in the journal, Science Immunology.
Researchers from the Universities of Aberdeen and Manchester examined how CLPs — specifically Ym1 (Chil3) and Ym2 (Chil4) — behave in a mouse model exposed to common allergens, including house dust mite, ragweed and Aspergillus fumigatus. Traditionally associated with type 2 and type 17 immune responses, these proteins were found to exert distinct and potent effects on extracellular matrix (ECM) remodeling, a process that contributes to long‑term structural changes in the airways.
They discovered that the remodeling driven by CLPs occurs independently of the well‑known cytokines IL‑13 and IL‑17A, which are typically central to allergic and inflammatory pathways. Using genetically modified mice lacking either Ym1 or Ym2, the study demonstrated that each protein has a fundamental and nonredundant role in determining the composition and behavior of airway ECM during chronic disease progression.
One of the most promising findings was that antibody‑mediated inhibition of CLPs, even after lung pathology had already developed, could reverse airway remodeling, researchers noted. This reversal happened without reducing chronic inflammation, suggesting that structural changes in the lungs may be treatable even when inflammatory processes persist.
However, the study’s findings indicated the approach was not sufficient to reduce airway hyperresponsiveness (AHR), a hallmark symptom of asthma. Removing CLPs entirely had unintended consequences: mice lacking these proteins showed increased epithelial damage and loss of bronchial barrier integrity, indicating that CLPs can have both protective and harmful roles depending on context.
The study ultimately unravels chronic cytokine signaling from the physical remodeling of the airways — two processes often linked in asthma research. By revealing CLPs as essential orchestrators of airway structure, researchers indicated the findings provide a potential pathway for developing new treatments that target tissue remodeling directly, especially for patients whose disease progresses despite anti‑inflammatory therapies.
According to the study’s authors, the dual nature of CLPs — as both contributors to pathology and protectors of epithelial integrity — underscores the need for highly targeted approaches rather than broad suppression.
As asthma rates continue to rise globally, researchers noted that these insights represent an important step toward therapies that don’t just manage symptoms but address the structural roots of chronic airway disease.
